DOCSLIB.ORG

Alcohol, Tobacco and Other Drugs: Clinical Guidelines for Nurses and Midwives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alcohol, Tobacco and Other Drugs: Clinical Guidelines for Nurses and Midwives Alcohol, Tobacco and Other Drugs: Clinical Guidelines for Nurses and Midwives Version 3, 2012 Endorsed by the South Australian Alcohol and Drug Nursing and Midwifery Statewide Action Group This work is copyright. It may be reproduced in whole or in part for educational or training purposes subject to the inclusion of an acknowledgement of the source. Commercial usage or sale is not permissible without negotiation with the authors. Electronic Index: This publication is available as a down-loadable PDF with fully searchable text. To access PDF copies go to: www.dassa.sa.gov.au www.health.adelaide.edu.au/nursing For further information contact: The University of Adelaide School of Nursing Phone (08) 8303 3595 Email: [email protected] This work may be cited as: de Crespigny, C & Talmet, J. 2012. (Eds). Alcohol, Tobacco and Other Drugs: Clinical Guidelines for Nurses and Midwives. Version 3. The University of Adelaide School of Nursing, Drug and Alcohol Services, South Australia. Subject Keywords: Alcohol, Tobacco, Other Drugs, Drug and Alcohol, Substances, Clinical Guidelines, Nurses, Midwives. For Cataloguing-in-Publication data please contact National Library of Australia: [email protected] ISBN 978-0-9803130-8-6 First printing Version 1 2003 Second printing Version 2 2003 Third printing Version 3 2012 © University of Adelaide and Drug & Alcohol Services, South Australia 2012 Foreword The use of alcohol, tobacco and other drugs (ATOD) is prevalent in our society. Nurses, midwives and other health care professionals are faced with a diverse group of consumers many of whom are affected either temporarily or in the longer term by ATOD related health challenges. These challenges include intoxication, withdrawal, trauma, medical and mental health conditions, and social issues. The complexities of providing safe care to consumers affected by ATOD are unmistakable and challenging. The provision of safe care is at the core of good nursing and midwifery practice. For nurses and midwives to do this they require reliable evidence based clinical guidelines that are accessible and easy to use. These guidelines aim to support and provide a benchmark for quality assessment, intervention and referral by nurses and midwives in their daily practice. Clinicians should aim to use these guidelines within the context of their roles and scopes of practice and, to update their knowledge base by accessing current research and clinical guidelines as they emerge. To this end I draw your attention to the information, links to key resources and websites listed at the back of this publication. Ms Lydia Dennett Chief Nurse and Midwifery Officer Nursing and Midwifery Office Department for Health and Ageing i Contents FOREWORD................................................................................................................................................. I CONTENTS ................................................................................................................................................. II LIST OF FIGURES ........................................................................................................................................ VII LIST OF TABLES ......................................................................................................................................... VIII PURPOSE AND PRINCIPLES ............................................................................................................................IX Statement of purpose ....................................................................................................................... ix Principles for practice ....................................................................................................................... ix ACKNOWLEDGEMENTS ................................................................................................................................. X GLOSSARY ................................................................................................................................................ XII USEFUL RESOURCES AND INFORMATION ........................................................................................................ XIX Blood Borne Viruses ....................................................................................................................... xxii Useful Websites .............................................................................................................................. xxii Peer reviewed journals ................................................................................................................... xxii Professional Resources .................................................................................................................. xxiii Relevant services and community groups ..................................................................................... xxiv LIST YOUR OWN CONTACT NUMBERS ........................................................................................................... XXVI SECTION 1 BASIS FOR PRACTICE ........................................................................................................... 1 1.1 ALCOHOL, TOBACCO AND OTHER DRUG USE ........................................................................................... 2 Introduction ....................................................................................................................................... 2 Poly drug use ..................................................................................................................................... 2 Patterns of ATOD use ........................................................................................................................ 3 Myths ................................................................................................................................................ 4 1.2 HARM MINIMISATION ......................................................................................................................... 5 Introduction ....................................................................................................................................... 5 Harm reduction ................................................................................................................................. 5 Demand reduction ............................................................................................................................. 6 Supply reduction ................................................................................................................................ 7 1.3 NON-JUDGEMENTAL CARE ................................................................................................................... 8 Barriers to people seeking help ......................................................................................................... 8 Engaging people in treatment and care ............................................................................................ 9 1.4 UNDERSTANDING ATOD PROBLEMS ................................................................................................... 10 Theories ........................................................................................................................................... 10 Integrating the models in practice .................................................................................................. 16 ii SECTION 2 CLIENT CARE ...................................................................................................................... 17 2.1 COMMUNICATION AND CULTURAL ISSUES ............................................................................................. 18 Introduction ..................................................................................................................................... 18 General principles of communication .............................................................................................. 18 Working effectively with Indigenous People ................................................................................... 21 Working with young people and children ....................................................................................... 28 2.2 ASSESSMENT .................................................................................................................................. 30 Introduction ..................................................................................................................................... 30 Rationale for assessment ................................................................................................................ 30 Using a person-centred approach ................................................................................................... 32 Issues for assessment ...................................................................................................................... 33 Nursing guidelines—general assessment ........................................................................................ 37 Pattern and recent history of ATOD use .......................................................................................... 37 Physical assessment ........................................................................................................................ 41 Planning care ..................................................................................................................................
Load more

Recommended publications
  • Alloimmunization in Pregnancy
    Maternal Cannabis Use in Pregnancy and LactationAlloimmunization in Jamie Lo MD MCR, Assistant Professor MaternalJamiePregnancy FetalLo MD Medicine Oregon Health & Science University DecemberDATE: September 18, 2020 23, 2016 Disclosures • I have no relevant financial relationships to disclose or conflicts of interest to resolve Manzanita, Oregon Marijuana Legalization Trend • Marijuana is the most commonly used illicit drug in pregnancy • 33 states and Washington DC have legalized medical marijuana • 11 states and Washington DC have legalized recreational marijuana • To address the opioid crisis, 3 states have passed laws to allow marijuana to be prescribed in place of opioids References: www.timesunion.com/technology/businessinsider/article/This-map-shows-every-state-that-has-legalized-12519184.php, Accessed October 10, 2020 Understanding the Impact of Legalization Reference: NW HIDTA Report What is marijuana? • Cannabis sativa plant • Contains over 600 chemicals – Delta-9-tetrahydrocannabinol (THC): main psychoactive component • Small and highly lipophilic • Rapidly distributed to the brain and fat • Metabolized by the liver • Half-life is 20-36hrs to 4-6 days • Detectable up to 30 days after using – Cannabidiol (CBD): second most prevalent main active ingredient Endocannabinoid System References: Nahtigal et al. J Pain Manage. 2016 Cannabidiol vs. Delta-9-tetrahydrocannabinol • CB1 receptor (found on neurons and glial cells in the brain) – Binding of THC results in euphoric effects – CBD has 100 fold less affinity to CB1 receptor than
    [Show full text]
  • Impact of Recreational and Medical Marijuana Use During Pregnancy and Lactation on the Newborn
    If it’s Legal it Can’t be all Bad… can it? Impact of Recreational and Medical Marijuana use during Pregnancy and Lactation on the Newborn Moni Snell MSN RN NNP-BC Neonatal Nurse Practitioner NICU Regina Qu’Appelle Health Region Objectives Understand the current use, risks and differences between medical (CBD) and recreational (THC) marijuana Discuss evidence based education for women and current management strategies for caring for newborns exposed to THC through pregnancy and breastfeeding Discuss the impact of increased newborn exposure to recreational and medical marijuana with it’s legalization Marijuana… common term for Recreational Cannabis in the form of dried leaves, stems or seeds Anticipated legalization in Canada July 2018 Currently legal in 29 states in the US Recreational use and self –medication with cannabis is very common • Cannabis: pot, grass, reefer, weed, herb, Mary Jane, or MJ Peak use is in the 20’s and 30’s : women’s • Contains over 700 chemicals, about 70 of reproductive years which are cannabinoids • Hash and hash oil also come from the cannabis plant Cannabis Ingredients Tetrahydrocannabinol (THC) is the chemical that makes people high Cannabidiol (CBD) is known for its medicinal qualities for pain, inflammation, and anxiety o CBD does not make you feel as high Different types of cannabis and effects depend on the amount of THC or CBD, other chemicals and their interactions THC content is known to have increased over the past several decades Oils have higher percentage of THC and THC in edible cannabis products can vary widely and can be potent THC content/potency of THC confiscated by DEA in US has been steadily increasing Consequences could be worse than in the past, especially among new users or in young people with developing brains ElSohly et al, (2016) Changes in cannabis potency over the last 2 decades (1995-2014): Analysis of current data in the United States.
    [Show full text]
  • Maternal Use of Cannabis and Pregnancy Outcome
    BJOG: an International Journal of Obstetrics and Gynaecology January 2002, Vol. 109, pp. 21–27 Maternal use of cannabis and pregnancy outcome David M. Fergussona, L. John Horwooda, Kate Northstoneb,*, ALSPAC Study Teamb Objective To document the prevalence of cannabis use in a large sample of British women studied during pregnancy, to determine the association between cannabis use and social and lifestyle factors and assess any independent effects on pregnancy outcome. Design Self-completed questionnaire on use of cannabis before and during pregnancy. Sample Over 12,000 women expecting singletons at 18 to 20 weeks of gestation who were enrolled in the Avon Longitudinal Study of Pregnancy and Childhood. Methods Any association with the use of cannabis before and during pregnancy with pregnancy outcome was examined, taking into account potentially confounding factors including maternal social background and other substance use during pregnancy. Main outcome measures Late fetal and perinatal death, special care admission of the newborn infant, birthweight, birth length and head circumference. Results Five percent of mothers reported smoking cannabis before and/or during pregnancy; they were younger, of lower parity, better educated and more likely to use alcohol, cigarettes, coffee, tea and hard drugs. Cannabis use during pregnancy was unrelated to risk of perinatal death or need for special care, but, the babies of women who used cannabis at least once per week before and throughout pregnancy were 216g lighter than those of non-users, had significantly shorter birth lengths and smaller head circumferences. After adjustment for confounding factors, the association between cannabis use and birthweight failed to be statistically significant ( P ¼ 0.056 ) and was clearly non-linear: the adjusted mean birthweights for babies of women using cannabis at least once per week before and throughout pregnancy were 90g lighter than the offspring of other women.
    [Show full text]
  • DEMAND REDUCTION a Glossary of Terms
    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
    [Show full text]
  • Alcohol Responsibly and Ending Tobacco Use, Plus Caffeine - Dr
    MHE-110 – Chapter Nine – Drinking Alcohol Responsibly and Ending Tobacco Use, plus Caffeine - Dr. Dave Shrock Chapter Nine Alcohol - an overview Alcohol and ending Tobacco Use 13th pp. 239-240; 12th pp. 232-223 • alcohol is the most widely used drug in the United (including caffeine) States • 86% of Americans consume alcohol 13th edition, pp. • 10% are heavy drinkers…who consume half of all the 241-269 alcohol produced 12th edition: • no other form of addiction or disability costs the US pp. 231-261 more than alcohol use/abuse annually Excessive alcohol use causes 88,000 deaths annually (chapter eight) twice as many as illicit drugs • lost work time, illness, insurance, accidents, medical costs take a toll on all of us…25% of all medical costs in the US are alcohol related Alcohol: The world’s most what is alcohol? dangerous drug? 13th, pp. 239-240; 12th pp. 232-233 The Lancet Medical Journal - 1 November, 2016 • alcohol is a byproduct of fermentation • In a recent article published in of vegetable or fruit pulp or ‘mash’ the British medical journal The this produces a concentration of Lancet, when considering the alcohol up to 14% drug’s damage to: • distillation is a further process by •one’s self capturing the vapors from heating • one’s family the mash, and mix this with water • the environment • proof is the measure of % of alcohol, which means the % • economic cost of alcohol is half of the ‘proof rating’ • Alcohol is the world’s most • some alcohol is 152 proof, or 71% alcohol most beers are damaging drug to individuals 8 proof, or 4% alcohol.
    [Show full text]
  • Psychostimulants Tobacco and Nicotine
    Psychostimulants Psychostimulants produce: • Increases in alertness. • Behavioral arousal. • Activation of sympathetic nervous system. • Sympathomimetic Effects Tobacco and Nicotine 1 Tobacco • Native Americans were the first to utilize tobacco. • Columbus discovered tobacco in the new world. • Tobacco use spread rapidly through Europe. Tobacco Preparations • Smoking Tobacco • Chewing Tobacco • Snuff Active ingredient is nicotine. • Named after Nicotiana. • Found only in tobacco. Behavioral / Physiological Effects of Nicotine • Pleasure/Euphoria • Sympathomimetic effects. • Increases in alertness. • Maybe overestimated? • Appetite Suppressant/Nausea • Muscle Tremor • Nesbitt’s Paradox 2 Pharmacokinetics Inhalation Absorption • Very rapid absorption. • One cigarette contains 1-5 mg nicotine. • A smoker utilizes ≈1 mg of this nicotine. • Dose control is important. • Low tar/nicotine cigarettes? Oral/Nasal Absorption • Nicotine is basic, so G.I. tract absorption is poor. • Cigarette smoke makes the saliva acidic. • Nicotine poorly absorbed in mouth. • Pipe and cigar smoke isn’t acidic. • Nicotine easily absorbed in mouth. • Nicotine from chewed tobacco and snuff absorbed through oral/nasal membranes. Nicotine easily crosses the blood brain barrier. Metabolism • 80-90% metabolized by the liver. • Remainder secreted in urine. • Half-life of ≈1 hour. 3 Pharmacodynamics - Nicotine is an agonist at nicotinic ACh receptors. • In the PNS, nicotine: • Causes adrenal medulla to release norepinephrine and epinephrine. • Sympathomimetic Effects • Activates receptors at the neuromuscular junction. • Muscle Tremor In the CNS, nicotine activates presynaptic axo-axonic receptors. A x o n 2 N T N T N T NT NT Axon 1 Dendrite NT Increases NT release from Axon 1. • Presynaptic Facilitation Many different NTs can be facilitated. • DA in the Nucleus Accumbens • Catecholamines in brainstem arousal centers.
    [Show full text]
  • The Effects of Adenosine Antagonists on Distinct Aspects of Motivated Behavior: Interaction with Ethanol and Dopamine Depletion
    Facultat de Ciències de la Salut Departament de Psicologia Bàsica, Clínica i Psicobiologia The effects of adenosine antagonists on distinct aspects of motivated behavior: interaction with ethanol and dopamine depletion. PhD Candidate Laura López Cruz Advisor Dr. Mercè Correa Sanz Co-advisor Dr. John D.Salamone Castelló, May 2016 Als meus pares i germà A Carlos AKNOWLEDGEMENTS This work was funded by two competitive grants awarded to Mercè Correa and John D. Salamone: Chapters 1-4: The experiments in the first chapters were supported by Plan Nacional de Drogas. Ministerio de Sanidad y Consumo. Spain. Project: “Impacto de la dosis de cafeína en las bebidas energéticas sobre las conductas implicadas en el abuso y la adicción al alcohol: interacción de los sistemas de neuromodulación adenosinérgicos y dopaminérgicos”. (2010I024). Chapters 5 and 6: The last 2 chapters contain experiments financed by Fundació Bancaixa-Universitat Jaume I. Spain. Project: “Efecto del ejercicio físico y el consumo de xantinas sobre la realización del esfuerzo en las conductas motivadas: Modulación del sistema mesolímbico dopaminérgico y su regulación por adenosina”. (P1.1B2010-43). Laura López Cruz was awarded a 4-year predoctoral scholarship “Fornación de Profesorado Universitario-FPU” (AP2010-3793) from the Spanish Ministry of Education, Culture and Sport. (2012/2016). TABLE OF CONTENTS ABSTRACT ...................................................................................................................1 RESUMEN .....................................................................................................................3
    [Show full text]
  • Cannabis & Human Milk
    CANNABIS & HUMAN MILK Two recent studies about cannabis use while breaseeding, both done with Colorado connecons, may have implicaons for your paents. With marijuana use during pregnancy and lactaon on the rise due to legalizaon in more states, these researchers are filling a gap in knowledge about this important health topic. The first study, conducted by Thomas Hale PhD and colleagues, looked at the transfer of tetrahydrocannabinol (THC) into human milk aer maternal inhalaon of a prescribed amount of cannabis. Eight anonymous women from Colorado enrolled in the study and were instructed to disconnue any cannabis use for 24 hours, provide a sample of their milk, then smoke the prescribed amount of cannabis and collect milk at 20 minutes, one, two and four hours. The results showed that THC was transferred into milk at 2.5% of the maternal dose. The second study, done by researchers at the University of Colorado (CU) School of Public Health, used Pregnancy Risk Assessment Monitoring System (PRAMS) data from 2014 and 2015. In this group, 5.7% reported using marijuana during pregnancy and 5% during breaseeding. They discovered that prenatal marijuana use was associated with a 50% increased chance of low birth weight in babies regardless of tobacco use. Prenatal marijuana use was four mes higher among women who were younger, less educated, received Medicaid or WIC, were white, unmarried and lived in poverty. The study suggests that prenatal cannabis use has a detrimental impact on a baby's brain funcon starng in toddlerhood, specifically issues related to aenon deficit disorder. 88% of women who use cannabis in pregnancy also breaseed their babies.
    [Show full text]
  • Pregnant People's Perspectives on Cannabis Use During
    Pregnant people's perspectives on cannabis use during pregnancy: A systematic review and integrative mixed-methods research synthesis Meredith Vanstone1, Janelle Panday1, Anuoluwa Popoola1, Shipra Taneja1, Devon Greyson2, Sarah McDonald1, Rachael Pack3, Morgan Black1, Beth Davis1, and Elizabeth Darling1 1McMaster University 2University of Massachusetts Amherst 3Schulich School of Medicine and Dentistry March 17, 2021 Abstract Background: Cannabis use during the perinatal period is rising. Objectives: To synthesize existing knowledge on the per- spectives of pregnant people and their partners about cannabis use in pregnancy and lactation. Search strategy: We searched MEDLINE, APA PsycINFO, Cumulative Index to Nursing and Allied Health Literature, Social Science Citation Index, Social Work Abstracts, ProQuest Sociology Collection up until April 1, 2020. Selection criteria: Eligible studies were those of any methodology which included the perspectives and experiences of pregnant or lactating people and their partners on cannabis use during pregnancy or lactation, with no time or geographical limit. Data collection and analysis: We employed a convergent integrative approach to the analysis of findings from all studies, using Sandelowski's technique of \qualitizing statements" to extract and summarize relevant findings from inductive analysis. Main results: We identified 23 studies of pregnant people's views about cannabis use in pregnancy. Comparative analysis revealed that whether cannabis was studied alone or grouped with other substances resulted in significant diversity in descriptions of participant decision-making priorities and perceptions of risks and benefits. Studies combining cannabis with other substance seldom addressed perceived benefits or reasons for using cannabis. Conclusions: The way cannabis is grouped with other substances influences the design and results of research.
    [Show full text]
  • Marijuana: the Effects on Pregnancy, the Fetus, and the Newborn
    Journal of Perinatology https://doi.org/10.1038/s41372-020-0708-z REVIEW ARTICLE Marijuana: the effects on pregnancy, the fetus, and the newborn Gilbert I. Martin1,2 Received: 10 February 2020 / Revised: 18 May 2020 / Accepted: 28 May 2020 © The Author(s), under exclusive licence to Springer Nature America, Inc. 2020 Abstract There is growing evidence that there is an increased use of Marijuana (cannabis) during the perinatal period. This review summarizes pertinent legislation (past and present) and the physiology and pathophysiology of cannabis use during pregnancy. The literature which involves issues concerning cannabis and pregnancy is expanding but at present has many gaps and unanswered questions. The effects on the newborn are significant and treatment recommendations including breastfeeding are presented. Also included is a description of developmental delay during the first 2 years of life in infants exposed to prenatal marijuana. In addition, this commentary discusses the increase use of the newer “synthetic” cannabinoids which have greater psychotropic activity and can cause significant harm. 1234567890();,: 1234567890();,: Introduction United States Federal Bureau of Narcotics produced litera- ture saying that marijuana was an addicting substance Throughout the world the use of marijuana for both med- which led users to narcotics addiction. It was then portrayed icinal and recreational use has increased dramatically over as a “gateway drug”. The Marijuana Tax Act of 1937 placed the past decade and especially in the last few years. Along a tax on the sale of cannabis [1]. In the 1950s marijuana was with the opioid crisis, the use of many drugs has become known as an accessory to the “beat generation”.
    [Show full text]
  • Cannabis and Pregnancy Transitioning Into Legalization
    Cannabis and Pregnancy Transitioning into Legalization Phase 2 Report January 2020 TBDHU.COM SectionCannabis Footer and Pregnancy: Transitioning into Legalization 1 Acknowledgements The Thunder Bay District Health Unit wishes to acknowledge the following for their contribution to this report, Thunder Bay District Health Unit Staff: Stephanie Commisso Sarah Hyett Jennifer McFarlane Adena Miller Janice Piper-Wilson Eryn Pleson Sunny Samira Erica Sawula Lyne Soramaki Sophia Wenzel Individuals and community partners from the District of Thunder Bay who provided feedback to the Community Perception Survey on Cannabis and Pregnancy (CPSCP). 2 Table of Contents Acknowledgements .............................................................................................................................2 Guide to Acronyms Used .....................................................................................................................4 Notes About the Study .......................................................................................................................5 Executive Summary ..............................................................................................................................6 About The Cannabis and Pregnancy Research Project ...................................................................10 Phase One - Cannabis and Pregnancy: Getting Ahead of Policy (TBDHU, 2018) .........................10 Phase Two - Cannabis and Pregnancy: Transitioning Into Legalization .........................................11
    [Show full text]
  • Examining Views on Medical Marijuana
    VOL. 111, NO. 1 | QUARTER 1, 2018 Examining views on medical marijuana 2018 Legislative Agenda 2018 TMA Voter Guide The Truth About Balance Billing tnmed.org VOL. 111,XXX, NO. NO. 1 X | | QUARTER QUARTER 1, 1, 2018 2018 Table of Contents PRESIDENT 3 Legislative Agenda NITA W. SHUMAKER, MD TMA to focus on payment reforms, scope of practice, CHIEF EXECUTIVE OFFICER public health issues RUSS MILLER, CAE EDITOR DAVID G. GERKIN, MD 5 Editorial: Another Tool to Reduce MANAGING EDITOR Narcotic Overdose Deaths in Tennessee JULIA COUCH Matthew Hines, MD EDITORIAL BOARD JAMES FERGUSON, MD KARL MISULIS, MD 7 Editorial: A Hospice Doctor Looks at GREG PHELPS, MD BRADLEY SMITH, MD Medical Marijuana JONATHAN SOWELL, MD Greg Phelps, MD ANDY WALKER, MD ADVERTISING REPRESENTATIVE 13 Ask TMA MICHAEL HURST 615.385.2100 [email protected] 14 The Truth about Surprise Medical Bills Douglas Springer, MD and Jonathan Hughes, MD 16 Ruffner: Marijuana Update from AMA 18 Guide to 2018 TMA Leadership Elections 24 For the Record Tennessee Medicine: Journal of the Tennessee Medical Association (ISSN 10886222) is published Quarterly by the Tennessee Medical Association, 701 Bradford Ave., Nashville, TN 37204. Tennessee Medical Association is a nonprofit organization with a definite membership for scientific and educational purposes, devoted to the interests of the medical profession of Tennessee. This Association is not responsible for the authenticity of opinion or statements made by authors or in communications submitted to Tennessee Medicine for publication. The author or communicant shall be held entirely responsible. Advertisers must conform to the policies and regulations established by the Board of Trustees of the Tennessee Medical Association.
    [Show full text]